Viatris Says Wakix Wins Japan Approval for Narcolepsy, Obstructive Sleep Apnea

07:27 AM EDT, 09/16/2026 (MT Newswires) -- Viatris (VTRS) said Wednesday that Japan's health ministry approved Wakix, or pitolisant, as treatment for narcolepsy types 1 and 2 and for excessive daytime sleepiness linked to obstructive sleep apnea syndrome. The approval was supported by data from phase 3 trials in Japan and international studies in narcolepsy and obstructive sleep apnea patients with excessive daytime sleepiness despite continuous positive airway pressure therapy, the company said.